Proactive Investors - Run By Investors For Investors

Sareum Holdings jumps as it says new data on cancer drug to be released at top conference

The update is being presented in the form of two abstracts at the American Society of Clinical Oncology in Chicago
ovarian cancer graphic
Being trialled are two different approaches to treating ovarian cancer

Sareum Holdings PLC (LON:SAR) shares jumped on Tuesday as the firm said data from a potential cancer drug it developed will be showcased at the world’s leading oncology conference.

Updated results from a Phase I/IIa studies carried out on SRA737 by licensing partner Sierra Oncology will be delivered in the form of two abstracts at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on June 1.

The Sareum-discovered drug candidate is what’s known as a checkpoint kinase 1 (CHK1) inhibitor.

CHK1 controls a cancer cell's response to DNA damage, which could be caused by the disease itself or intentionally by chemotherapy or radiotherapy.

The new treatment is being trialled in women with ovarian cancer, both as a single therapy and in harness with chemotherapy called gemcitabine.

The ASCO abstracts cover new data on the two approaches to treating the killer disease.

In afternoon trading, Sareum shares were 7.1% higher at 0.75p.

 -- Adds share price --

View full SAR profile View Profile

Sareum Holdings PLC Timeline

Big Picture
February 22 2019

Related Articles

1538160791_petri-dishes.jpg
September 28 2018
The biotech group revealed it had brought in $9.1mln via an oversubscribed placing
Hep C
November 22 2018
The company made positive operational progress in the year to June 30.
A stomach adenocarcinoma
February 13 2019
The company’s B-cell peptide cancer vaccines have shown promise in pre-clinical and early-stage study.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use